The GAP-BRAIN trial randomized patients with untreated EGFR-mutant NSCLC BrMs to gefitinib alone or gefitinib with pemetrexed and platinum chemotherapy [119]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.